Antero updated its full-year NGL price guidance slightly downward, attributing the revision to Q2 actuals impacted by inventory adjustments, but continues to expect premiums in the second half of the ...

We sifted through the Finviz stock screener to compile a list of the top 10 biotech stocks with an upside potential of over ...

Approval is based on results from the Phase III VALIANT trial (NCT05067127), in which Empaveli demonstrated a 68% reduction ...

Biomarkers at 6-week interim analysis show a positive impact on fibrogenesis, fibrolysis and potentially the initiation of a repair response ...

As Lollapalooza returns to Chicago’s Grant Park this weekend, organizers are once again turning up the volume on ...

Airports across the UK are enforcing different 100ml liquid systems, threatening to cause hold-ups in security lanes as the ...

C3.ai (NYSE: AI) is generating accelerating revenue growth and improving free cash flow. It also boasts a pristine balance sheet. Where to invest $1,000 right now? Our analyst team just revealed what ...

C3.ai, Inc. AI is capitalizing on the booming demand for enterprise AI. However, the company now faces a critical challenge.

M&A is back is in style again under President Donald Trump. That’s good news for investors in stocks such as C3.ai, Viking ...

Pegcetacoplan inhibits C3 activation by binding to C3 and its activation fragment C3b, thereby reducing C3 glomerular fragment deposition in patients with C3G and primary IC-MPGN.

C3 glomerulopathy (C3G) and immune-complex membranoproliferative glomerulonephritis (IC-MPGN) are two diseases that have a ...

Founded in 2009 by Thomas Siebel, C3.ai's core purpose has always been to deliver AI solutions to enterprises. Its value ...